1. Home
  2. Companies
  3. TTX
  4. Material Events

Tetratherix (ASX:TTX) — Material Events

ASX:TTX · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 14 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
Tetratherix Secures $25M IPO, Strikes Bio Optix Licensing Deal, Advances FDA PathwaysHigh
Tetratherix signs Bio Optix licensing deal, completes FDA pre-submission, raises $25M in ASX IPO
23 July 2025 ·Quarterly Activities Report ·85
Tetratherix’s TetraDerm Slashes Scar Scores in Major Clinical BreakthroughMedium
Tetratherix reports promising interim clinical results for scar prevention product TetraDerm
17 Feb 2026 ·Clinical Trial Update ·85
Tetratherix Secures $5M to Accelerate Tutelix Prostate Spacer TrialMedium
Tetratherix advances Tutelix prostate spacer with $5M Series A, progressing to pivotal US-Australia trial
10 Mar 2026 ·ASX Release ·85
Tetratherix Accelerates Growth with New Partnerships and Manufacturing ExpansionMedium
Tetratherix advances clinical programs, secures strategic partnerships, and expands manufacturing with strong cash position
28 Jan 2026 ·Quarterly Activities Report ·85
Tetratherix Posts $9.4M Loss, Advances Key Clinical and Manufacturing Milestones Post-IPOHigh
Tetratherix reports $9.4M FY25 loss, completes ASX IPO, advances clinical and manufacturing milestones
28 Aug 2025 ·Annual Report ·85
Tetratherix Unveils Precision Medicine Franchise with $3M Annual US DealHigh
Tetratherix launches precision medicine franchise with exclusive US partnership, securing $3M annual license revenue
16 Mar 2026 ·ASX Release ·85
Tetratherix Advances Clinical Trials and Secures Global Supply Deals Amid $4.6m H1 LossMedium
Tetratherix reports AUD 4.6m H1 loss, advances clinical trials and secures key global supply agreements
24 Feb 2026 ·Interim Report ·85
Tetratherix Advances Tutelix Trial and Expands Manufacturing with $3.3M GrantMedium
Tetratherix reports positive Tutelix trial results, secures $3.3M government grant, and expands manufacturing capacity
27 Oct 2025 ·Quarterly Activities Report ·85
Tetratherix Raises $17M to Accelerate Manufacturing and Commercial GrowthHigh
Tetratherix raises $15M placement plus $2M SPP to accelerate commercial growth and manufacturing expansion
28 May 2026 ·Capital Raising ·85
Tetratherix Secures Global Deal with Henry Schein, Sets Stage for 2026 LaunchMedium
Tetratherix Secures Global Distribution Deal with Henry Schein and Begins Manufacturing Facility Construction
19 Jan 2026 ·Commercial Agreement ·85
Tetratherix Advances TetraDerm Trial to Final Cohort with Strong Safety ResultsMedium
Tetratherix Advances TetraDerm Trial to Final Cohort with Strong Safety Results
13 Jan 2026 ·ASX Release ·80
Tetratherix Secures $3.3M Grant to Boost Polymer Production and US LaunchMedium
Tetratherix awarded $3.3M Australian Government grant to expand production and support US market launch
14 Aug 2025 ·ASX Release ·80
Tetratherix Unveils Scalable Tetramatrix Platform Targeting $6.8B MarketMedium
Tetratherix advances Tetramatrix™ platform with strong IP, manufacturing scale-up, and strategic partnerships targeting $6.8B market
28 Aug 2025 ·Investor Presentation ·80
Tetratherix Advances Commercialisation with $29.3M Cash, Posts $9.4M FY25 LossMedium
Tetratherix posts $9.4M statutory loss in FY25 with strong $29.3M cash post-IPO, advances commercialisation
28 Aug 2025 ·Financial Results ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.